ClinicalTrials.gg
TerminatedNCT02093221Updated Sep 5, 2018Results posted

Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

A Phase 2 interventional study of 180 mg/kg Alpha1-PI and 90 mg/kg Alpha1-PI in Type 1 Diabetes Mellitus, sponsored by Grifols Therapeutics LLC. Terminated at 36 sites in United States. Open to participants aged 6 Years to 35 Years. Per ClinicalTrials.gov, last updated 2018-09-05.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment

Why this study was terminated
Wk 52 primary endpoint results would be unaffected by follow-up data so trial was discontinued prior to wk 104. No safety data was collected after wk 52.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
6 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Enrollment
413th of 1,242
76 · median 40
Started
2014
with 56 others
Phase 2
188 of 1,458
24 open now
Registered
563rd of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 413th largest by enrollment of the 1,242 interventional ones that give a count, is one of 57 that started in 2014, is one of 188 in phase 2, and was the 563rd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 6 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, partial-blinded, five-arm, placebo-controlled study of human plasma-derived alpha1-proteinase inhibitor (alpha1-PI) in children (ages 6-11 years old) and teens/adults (ages 12-35 years old) with new onset Type 1 Diabetes Mellitus (T1DM). Currently enrolling ages 12-35 only. Once 25 patients are randomized and data is reviewed enrollment will be opened to the child cohort. The purpose of this study is to evaluate the safety and efficacy of four dosing regimens of human plasma-derived alpha1-PI in T1DM.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Type 1 Diabetes Mellitus
  • Alpha1-Proteinase Inhibitor
  • Beta Cell
  • Alpha1-Antitrypsin
04

Who can participate

Ages eligible
6 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of T1DM according to the ADA criteria.
  • Current use of injected insulin therapy and one positive result on testing for any of the following antibodies (If not currently on insulin therapy, must have positive result for at least two of the below antibodies):

    • Anti-islet-cell antibodies (islet cell antigen 512, insulinoma associated protein 2),
    • Anti-glutamic acid decarboxylase antibodies, or
    • Anti-insulin antibodies (unless received insulin therapy for > 7 days).
  • (BMI) ≤ 28 kg/m2 for adults (≥ 20 years of age) OR ≤ 90th percentile in accordance with the Centers for Disease Control BMI assessment for children and teens (2 through 19 years old).

Exclusion criteria

Exclusion Criteria:

  • History of or current diabetic retinopathy, neuropathy, or nephropathy.
  • Known thrombophilia or history of thrombosis.
  • Malignant disease (including malignant melanoma; however, other forms of skin cancer are allowed) within five years of randomization.
  • Active Hepatitis A virus, virus, virus, or infection.
  • History of anaphylaxis or severe systemic response to any plasma-derived alpha1-PI preparation or other blood product(s).
  • Known selective or severe Immunoglobulin A deficiency.
  • Elevated liver enzymes (, alanine aminotransferase, and alkaline phosphatase) equal to or greater than 2.5 times the .
  • Therapy with exenatide or any other agents that stimulate pancreatic β cell regeneration or insulin secretion, or any antidiabetic agents (oral or parenteral) other than insulin within one month prior to screening.
  • Use of omega-3 fatty acid supplements, including fish oil, within seven days prior to screening.
  • Current or planned therapy with inhaled insulin, if it becomes available.
  • Chronic use of systemic , with the exception of inhaled steroids, above a stable dose equivalent to 5 mg/day prednisone (e.g., 10 mg every 2 days) within 4 weeks prior to randomization. It is recommended to maintain the same dose throughout the study. (Note: Subjects with conditions (i.e., asthma) necessitating treatment with systemic short-term corticosteroids and administered a rapid taper are eligible per protocol with the caveat that the tapering is complete or decreased to the minimum requirement (i.e., 5 mg/day) at least 1 week prior to the Baseline visit (when randomization occurs) to ensure the subject is stable. For longer term steroid usage, please consult the Grifols Medical Monitor before considering the subject for study participation.)
  • Treatment with or cytostatic agents within 6 months of randomization.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Alpha1-PI 180 mg/kg/wk, 26 weeks

    180 mg/kg weekly infusions of Alpha1-PI for 26 weeks.

    Biological: 180 mg/kg Alpha1-PI

  • Experimental
    90 mg/kg/wk Alpha1-PI, 26 weeks

    90 mg/kg weekly infusions of Alpha1-PI for 26 weeks.

    Biological: 90 mg/kg Alpha1-PI

  • Placebo comparator
    Placebo, 26 weeks

    Weekly infusions of placebo for 26 weeks.

    Biological: Placebo

  • Experimental
    180 mg/kg/wk Alpha1-PI, 13 weeks

    180 mg/kg weekly infusions of Alpha1-PI for 13 weeks.

    Biological: 180 mg/kg Alpha1-PI

  • Experimental
    90 mg/kg/wk Alpha1-PI, 13 weeks

    90 mg/kg weekly infusions of Alpha1-PI for 13 weeks

    Biological: 90 mg/kg Alpha1-PI

  • Placebo comparator
    Placebo, 13 weeks

    Weekly infusions of placebo for 13 weeks.

    Biological: Placebo

Interventions

  • Biological180 mg/kg Alpha1-PI

    Drug page: Alpha 1-Antitrypsin

    Also known as: Alpha1-antitrypsin, Prolastin-C, Alpha1-Proteinase Inhibitor (human), Modified Process, Alpha-1 MP

  • Biological90 mg/kg Alpha1-PI

    Drug page: Alpha 1-Antitrypsin

    Also known as: Alpha1-antitrypsin, Prolastin-C, Alpha1-Proteinase Inhibitor (human), Modified Process, Alpha-1 MP

  • BiologicalPlacebo
06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mixed Meal Tolerance Test (MMTMT) Stimulated C-peptide 2 Hour Area Under the Concentration-time Curve (AUC)

    C-peptide concentration during MMTT with high protein energy drink. "Dose" for time frame refers to intake of high protein energy drink.

    Time frame: Baseline, Week 52 (pre-high protein drink and 15, 30, 60, 90, 120 minutes post-drink)

Secondary outcomes

  1. Change From Baseline for MMTT Stimulated C-peptide 2h AUC

    Time frame: Baseline, Weeks 14, 27, 39, 69, 87, and 104 (pre-high protein drink and 15, 30, 60, 90, 120 minutes post-drink)

  2. Change From Baseline for HbA1c Levels

    Time frame: Baseline, Weeks 14, 27, 39, 52, 69, 87, and 104

  3. Number of Subjects With Overall Severe Hypoglycemic Episodes

    Severe hypoglycemia defined according the ADA Workgroup on Hypoglycemia definition, as follows: An event requiring assistance of another person to actively administer carbohydrate, glucagons, or other resuscitative actions.

    Time frame: 104 weeks

  4. Change From Baseline for Mean Daily Insulin Dose Requirements

    Time frame: Baseline, Weeks 2, 4, 14, 27, 39, 52, 69, 87, and 104

  5. Change From Baseline for Mean Daily Glucose Levels Prior to Meals and Bedtime

    For each visit, the mean daily glucose levels were calculated over the previous 3-7 days prior to the study visit from blood glucose levels recorded daily prior to meals and bedtime.

    Time frame: Baseline, Weeks 2, 4, 14, 27, 39, 52, 69, 87, and 104

07

Results

Posted Apr 19, 2018

Participant flow

Participant flow — Overall Study
MilestoneAlpha1-PI 180 mg/kg/wk, 26 Weeks180 mg/kg/wk Alpha1-PI, 13 Weeks90 mg/kg/wk Alpha1-PI, 26 Weeks90 mg/kg/wk Alpha1-PI, 13 WeeksPlacebo
Started1516151515
Completed58677
Not completed108988
Withdrew: Adverse event10000
Withdrew: Withdrawal by subject11411
Withdrew: Lost to follow-up20110
Withdrew: Death01000
Withdrew: Protocol violation01000
Withdrew: Study termination65467

Outcome measures

PrimaryChange From Baseline in Mixed Meal Tolerance Test (MMTMT) Stimulated C-peptide 2 Hour Area Under the Concentration-time Curve (AUC)

C-peptide concentration during MMTT with high protein energy drink. "Dose" for time frame refers to intake of high protein energy drink.

Time frame:
Baseline, Week 52 (pre-high protein drink and 15, 30, 60, 90, 120 minutes post-drink)
Reported as:
Mean · min*nmol/L
Change From Baseline in Mixed Meal Tolerance Test (MMTMT) Stimulated C-peptide 2 Hour Area Under the Concentration-time Curve (AUC)
min*nmol/LAlpha1-PI 180 mg/kg/wk, 26 Weeks180 mg/kg/wk Alpha1-PI, 13 Weeks90 mg/kg/wk Alpha1-PI, 26 Weeks90 mg/kg/wk Alpha1-PI, 13 WeeksPlacebo
Change From Baseline in Mixed Meal Tolerance Test (MMTMT) Stimulated C-peptide 2 Hour Area Under the Concentration-time Curve (AUC)-32.357 ± 27.7184-25.171 ± 28.9450-21.682 ± 24.5787-34.393 ± 25.6837-16.909 ± 19.1278
SecondaryChange From Baseline for MMTT Stimulated C-peptide 2h AUC
Time frame:
Baseline, Weeks 14, 27, 39, 69, 87, and 104 (pre-high protein drink and 15, 30, 60, 90, 120 minutes post-drink)
Reported as:
Mean · min*nmol/L
Change From Baseline for MMTT Stimulated C-peptide 2h AUC
min*nmol/LAlpha1-PI 180 mg/kg/wk, 26 Weeks180 mg/kg/wk Alpha1-PI, 13 Weeks90 mg/kg/wk Alpha1-PI, 26 Weeks90 mg/kg/wk Alpha1-PI, 13 WeeksPlacebo
Week 14-19.396 ± 23.7789-0.444 ± 18.85954.427 ± 33.2220-12.725 ± 20.20513.317 ± 21.1784
Week 27-30.709 ± 21.2821-17.826 ± 21.04626.537 ± 56.1336-23.082 ± 22.3027-1.411 ± 26.8550
Week 39-28.500 ± 37.6682-17.664 ± 26.1729-23.342 ± 21.6945-36.580 ± 20.7765-10.808 ± 20.0078
Week 69-45.316 ± 27.1563-42.014 ± 15.7239-27.023 ± 28.6920-39.735 ± 23.3488-16.744 ± 21.8947
Week 87-42.487 ± 31.9418-43.012 ± 23.2403-34.590 ± 21.6148-47.496 ± 23.7717-32.561 ± 20.0826
Week 104-29.687 ± 25.5941-44.314 ± 28.0612-32.980 ± 18.2765-39.908 ± 26.4652-26.586 ± 20.6803
SecondaryChange From Baseline for HbA1c Levels
Time frame:
Baseline, Weeks 14, 27, 39, 52, 69, 87, and 104
Reported as:
Mean · percentage of change from baseline
Change From Baseline for HbA1c Levels
percentage of change from baselineAlpha1-PI 180 mg/kg/wk, 26 Weeks180 mg/kg/wk Alpha1-PI, 13 Weeks90 mg/kg/wk Alpha1-PI, 26 Weeks90 mg/kg/wk Alpha1-PI, 13 WeeksPlacebo
Week 14-0.68 ± 2.108-1.75 ± 2.543-1.16 ± 1.683-1.45 ± 1.812-2.64 ± 2.452
Week 27-0.67 ± 1.953-1.38 ± 2.799-0.74 ± 2.263-0.89 ± 2.740-2.52 ± 2.439
Week 39-0.58 ± 2.098-0.78 ± 3.043-0.40 ± 1.495-0.55 ± 2.798-1.52 ± 2.473
Week 52-0.47 ± 1.383-0.55 ± 3.437-0.25 ± 1.399-0.51 ± 2.504-1.52 ± 2.805
Week 69-0.01 ± 1.630-0.18 ± 2.5290.09 ± 1.197-0.33 ± 2.532-1.37 ± 3.004
Week 87-0.54 ± 1.310-0.38 ± 3.0350.30 ± 2.147-0.26 ± 2.608-0.89 ± 3.011
Week 104-0.76 ± 1.419-0.69 ± 2.4900.28 ± 1.987-0.10 ± 2.890-1.36 ± 2.155
SecondaryNumber of Subjects With Overall Severe Hypoglycemic Episodes

Severe hypoglycemia defined according the ADA Workgroup on Hypoglycemia definition, as follows: An event requiring assistance of another person to actively administer carbohydrate, glucagons, or other resuscitative actions.

Time frame:
104 weeks
Reported as:
Count of participants · Participants
Number of Subjects With Overall Severe Hypoglycemic Episodes
ParticipantsAlpha1-PI 180 mg/kg/wk, 26 Weeks180 mg/kg/wk Alpha1-PI, 13 Weeks90 mg/kg/wk Alpha1-PI, 26 Weeks90 mg/kg/wk Alpha1-PI, 13 WeeksPlacebo
1 episode12001
2 episodes00000
3 episodes00100
SecondaryChange From Baseline for Mean Daily Insulin Dose Requirements
Time frame:
Baseline, Weeks 2, 4, 14, 27, 39, 52, 69, 87, and 104
Reported as:
Mean · U/kg/day
Change From Baseline for Mean Daily Insulin Dose Requirements
U/kg/dayAlpha1-PI 180 mg/kg/wk, 26 Weeks180 mg/kg/wk Alpha1-PI, 13 Weeks90 mg/kg/wk Alpha1-PI, 26 Weeks90 mg/kg/wk Alpha1-PI, 13 WeeksPlacebo
Week 2-0.146 ± 0.2044-0.141 ± 0.2143-0.205 ± 0.2194-0.274 ± 0.1416-0.158 ± 0.2828
Week 4-0.147 ± 0.1405-0.264 ± 0.1456-0.201 ± 0.2058-0.220 ± 0.1744-0.150 ± 0.2788
Week 14-0.239 ± 0.2301-0.305 ± 0.1406-0.092 ± 0.1442-0.239 ± 0.1430-0.118 ± 0.1114
Week 27-0.040 ± 0.2313-0.033 ± 0.4310-0.090 ± 0.2117-0.138 ± 0.2321-0.135 ± 0.0607
Week 39-0.040 ± 0.32220.146 ± 0.7900-0.089 ± 0.2099-0.158 ± 0.2552-0.150 ± 0.1100
Week 520.226 ± 0.5861-0.037 ± 0.8720-0.055 ± 0.21800.214 ± 0.5898-0.320 ± 0.2906
Week 690.192 ± 0.54910.213 ± 0.60970.142 ± 0.59810.016 ± 0.7005-0.011 ± 0.2858
Week 870.517 ± 00.164 ± 0.53770.247 ± 0.65910.086 ± 0.5132-0.044 ± 0.4264
Week 1040.491 ± 0-0.168 ± 0.46500.307 ± 0.3772-0.015 ± 0.56260.303 ± 0
SecondaryChange From Baseline for Mean Daily Glucose Levels Prior to Meals and Bedtime

For each visit, the mean daily glucose levels were calculated over the previous 3-7 days prior to the study visit from blood glucose levels recorded daily prior to meals and bedtime.

Time frame:
Baseline, Weeks 2, 4, 14, 27, 39, 52, 69, 87, and 104
Reported as:
Mean · mmol/L
Change From Baseline for Mean Daily Glucose Levels Prior to Meals and Bedtime
mmol/LAlpha1-PI 180 mg/kg/wk, 26 Weeks180 mg/kg/wk Alpha1-PI, 13 Weeks90 mg/kg/wk Alpha1-PI, 26 Weeks90 mg/kg/wk Alpha1-PI, 13 WeeksPlacebo
Week 22.223 ± 3.62822.379 ± 2.75551.848 ± 1.12570.578 ± 1.68240.178 ± 1.5195
Week 42.343 ± 2.39421.856 ± 2.47502.106 ± 1.31440.759 ± 1.0403-0.158 ± 1.4665
Week 142.812 ± 2.59532.200 ± 2.12832.852 ± 3.03762.337 ± 3.9732-0.053 ± 1.4368
Week 271.782 ± 1.79212.252 ± 2.81732.446 ± 3.23553.471 ± 3.10430.577 ± 2.1475
Week 391.347 ± 2.06743.848 ± 2.22364.471 ± 2.73903.681 ± 4.04691.421 ± 2.1779
Week 522.995 ± 1.67033.067 ± 2.91603.242 ± 3.16362.723 ± 4.37490.616 ± 2.1868
Week 692.182 ± 1.335218.224 ± 41.14714.324 ± 4.41733.677 ± 3.73971.467 ± 4.2254
Week 873.354 ± 2.95503.101 ± 2.38593.234 ± 2.15163.835 ± 3.67604.863 ± 2.5173
Week 1042.545 ± 01.867 ± 2.45322.390 ± 1.54292.283 ± 6.10642.431 ± 1.4519

Adverse events

Collected over All AEs occurring after subject consent through Week 52 were collected. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alpha1-PI 180 mg/kg/wk, 26 Weeks0/15 (0%)0/15 (0%)10/15 (66.7%)
180 mg/kg/wk Alpha1-PI, 13 Weeks1/16 (6.3%)3/16 (18.8%)8/16 (50%)
90 mg/kg/wk Alpha1-PI, 26 Weeks0/14 (0%)0/14 (0%)11/14 (78.6%)
90 mg/kg/wk Alpha1-PI, 13 Weeks0/15 (0%)0/15 (0%)13/15 (86.7%)
Placebo0/15 (0%)0/15 (0%)11/15 (73.3%)
Most frequent serious events
Most frequent serious events
EventAlpha1-PI 180 mg/kg/wk, 26 Weeks180 mg/kg/wk Alpha1-PI, 13 Weeks90 mg/kg/wk Alpha1-PI, 26 Weeks90 mg/kg/wk Alpha1-PI, 13 WeeksPlacebo
Completed suicidePsychiatric disorders0/151/160/140/150/15
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/151/160/140/150/15
HyperglycaemiaMetabolism and nutrition disorders0/151/160/140/150/15
Most frequent other events
Showing 10 of 96
Most frequent other events
EventAlpha1-PI 180 mg/kg/wk, 26 Weeks180 mg/kg/wk Alpha1-PI, 13 Weeks90 mg/kg/wk Alpha1-PI, 26 Weeks90 mg/kg/wk Alpha1-PI, 13 WeeksPlacebo
Upper respiratory tract infectionInfections and infestations2/154/164/143/151/15
HeadacheNervous system disorders3/153/164/141/151/15
VomitingGastrointestinal disorders2/153/160/144/151/15
NasopharyngitisInfections and infestations2/150/163/143/152/15
ContusionInjury, poisoning and procedural complications0/150/163/140/151/15
NauseaGastrointestinal disorders1/153/161/140/152/15
GastroenteritisInfections and infestations0/152/162/140/150/15
SinusitisInfections and infestations1/151/162/140/151/15
ConstipationGastrointestinal disorders2/150/160/140/150/15
InfluenzaInfections and infestations2/150/160/140/150/15

Baseline characteristics

Age, Customized
Age, Customized(Participants)Alpha1-PI 180 mg/kg/wk, 26 Weeks180 mg/kg/wk Alpha1-PI, 13 Weeks90 mg/kg/wk Alpha1-PI, 26 Weeks90 mg/kg/wk Alpha1-PI, 13 WeeksPlaceboTotal
6 - 11 years2333213
12 - 17 years7777634
18 - 35 years6655729
Sex: Female, Male
Sex: Female, Male(Participants)Alpha1-PI 180 mg/kg/wk, 26 Weeks180 mg/kg/wk Alpha1-PI, 13 Weeks90 mg/kg/wk Alpha1-PI, 26 Weeks90 mg/kg/wk Alpha1-PI, 13 WeeksPlaceboTotal
Female6894431
Male986111145
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Alpha1-PI 180 mg/kg/wk, 26 Weeks180 mg/kg/wk Alpha1-PI, 13 Weeks90 mg/kg/wk Alpha1-PI, 26 Weeks90 mg/kg/wk Alpha1-PI, 13 WeeksPlaceboTotal
Hispanic or Latino313209
Not Hispanic or Latino121512131567
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alpha1-PI 180 mg/kg/wk, 26 Weeks180 mg/kg/wk Alpha1-PI, 13 Weeks90 mg/kg/wk Alpha1-PI, 26 Weeks90 mg/kg/wk Alpha1-PI, 13 WeeksPlaceboTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American010203
White141415131571
More than one race110002
Unknown or Not Reported000000
08

Study locations

36 sites
  • University of Arizona
    Tucson, Arizona 85724, United States
  • Clinica Medica San Miguel
    Los Angeles, California 90015, United States
  • Diabetes Associates Medical Group
    Orange, California 92868, United States
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
  • Metabolic Institute of America
    Tarzana, California 91356, United States
  • Ronald H Chochinov MD
    Ventura, California 93003, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06511, United States
  • Christiana Care Health Services
    Newark, Delaware 19713, United States
  • Solutions Through Advanced Research Inc.
    Jacksonville, Florida 32258, United States
  • CCM Clinical Research
    Miami, Florida 33133, United States
  • Advanced Pharma CR LLC
    Miami, Florida 33136, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30309, United States
  • Rocky Mountain Diabetes and Osteoporosis Center
    Idaho Falls, Idaho 83404, United States
  • Cook County Hospital
    Chicago, Illinois 60612, United States
  • Methodist Research Institute
    Indianapolis, Indiana 46202, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Barry J. Reiner MD, LLC.
    Baltimore, Maryland 21229, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Children's Hospitals and Clinics of Minnesota
    Saint Paul, Minnesota 55102, United States
  • Morristown Medical Center
    Morristown, New Jersey 07962, United States
  • University of New Mexico, Health Sciences Center
    Albuquerque, New Mexico 87131-0001, United States
  • Women and Children's Hospital
    Buffalo, New York 14222, United States
  • WakeMed Children's Hospital
    Raleigh, North Carolina 27610, United States
  • Endocrinology Associates Inc
    Columbus, Ohio 43201, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Pediatric Endocrinology, Genetics & Metabolism
    Oklahoma City, Oklahoma 73112, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19106, United States
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Rapid City Regional Hospital/Health Clinical Research
    Rapid City, South Dakota 57701, United States
  • Research Institute of Dallas
    Dallas, Texas 75231, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Northeast Clinical Research of San Antonio LLC
    San Antonio, Texas 78154, United States
  • University of Texas Health Science Center
    San Antonio, Texas 78229, United States
  • Consano Clinical Research
    San Antonio, Texas 78232, United States
09

References and documents

Publications

  • Lagarde WH, Courtney KL, Reiner B, Steinmann K, Tsalikian E, Willi SM. Human plasma-derived alpha1 -proteinase inhibitor in patients with new-onset type 1 diabetes mellitus: A randomized, placebo-controlled proof-of-concept study. Pediatr Diabetes. 2021 Mar;22(2):192-201. doi: 10.1111/pedi.13162. Epub 2020 Dec 13. PubMed 33244872 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Jan 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2014
First posted
Mar 20, 2014
Start
Mar 2014
Primary completionActual
Jan 2017
CompletionActual
Jun 2017
Results first posted
Apr 19, 2018
Last update
Sep 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02093221
Responsible party
Sponsor
First posted
Mar 20, 2014
Start date
Mar 2014
Primary completion
Jan 2017
Completion
Jun 2017
Results posted
Apr 19, 2018
Last update
Sep 5, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion